Drugs / PARENT OF TAS-303
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05621447 | Sep → Nov 2022 | — | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT04512053 | Sep 2020 → Dec 2021 | female stress incontinence | Taiho Pharmaceutical Co., Ltd. | Completed | Met primary |
| Phase 2 | NCT02906683 | Oct 2016 → Apr 2018 | female stress incontinence | Taiho Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02562807 Comparator | Oct → Dec 2015 | female stress incontinence | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PARENT OF TAS-303 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095507 ↗ |
| Known as | TAS-303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04512053 ↗ |
| Action | Inhibit | “a highly selective noradrenaline reuptake inhibitor” PMID 38979756 ↗ Jul 2024 |
| Modality | Small molecule | — CHEMBL5095507 ↗ |
| Route | Oral | “Oral administration for 8 weeks, once daily.” NCT02906683 ↗ |